IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v25y2024i8d10.1007_s10198-023-01655-x.html
   My bibliography  Save this article

AOTMiT reimbursement recommendations compared to other HTA agencies

Author

Listed:
  • Aneta Mela

    (Medical University of Warsaw)

  • Dorota Lis

    (HealthQuest Sp z o.o. Sp. K)

  • Elżbieta Rdzanek

    (Medical University of Warsaw)

  • Janusz Jaroszyński

    (Maria Curie-Skłodowska University of Lublin)

  • Marzena Furtak-Niczyporuk

    (Medical University of Lublin)

  • Bartłomiej Drop

    (Medical University of Lublin)

  • Tomasz Blicharski

    (Medical University of Lublin)

  • Maciej Niewada

    (Medical University of Warsaw)

Abstract

Our objective was to compare AOTMiT (Polish: Agencja Oceny Technologii Medycznych i Taryfikacji) recommendations to other HTA (Health Technology Assessment) agencies for newly registered drugs and new registration indications issued by the European Medicines Agency between 2014 and 2019. The study aims to assess the consistency and justifications of AOTMiT recommendations compared to that of other HTA agencies in 11 countries. A total of 2496 reimbursement recommendations published by 12 HTA agencies for 464 medicinal products and 525 indications were analyzed. Our analysis confirmed that the Polish AOTMiT agency seems to bear the closest resemblance to the corresponding HTA agencies from Canada (CADTH) and New Zealand (PHARMAC), when it comes to the outcome of HTA recommendations (positive or negative). Poland had a general scheme for justifying recommendations, similar to that of Ireland—four aspects (i.e., clinical efficacy, safety profile, cost-effectiveness, and impact on the payer’s budget) are important for Poland when formulating the final decision. Compared to other countries, Poland shows a noticeably different pattern of justifying reimbursement recommendations, as revealed primarily in terms of budget impact and somewhat less so for cost-effectiveness rationales.

Suggested Citation

  • Aneta Mela & Dorota Lis & Elżbieta Rdzanek & Janusz Jaroszyński & Marzena Furtak-Niczyporuk & Bartłomiej Drop & Tomasz Blicharski & Maciej Niewada, 2024. "AOTMiT reimbursement recommendations compared to other HTA agencies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(8), pages 1291-1310, November.
    • Handle: RePEc:spr:eujhec:v:25:y:2024:i:8:d:10.1007_s10198-023-01655-x
    DOI: 10.1007/s10198-023-01655-x
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-023-01655-x
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-023-01655-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Kawalec, Paweł & Sagan, Anna & Stawowczyk, Ewa & Kowalska-Bobko, Iwona & Mokrzycka, Anna, 2016. "Implementation of the 2011 Reimbursement Act in Poland: Desired and undesired effects of the changes in reimbursement policy," Health Policy, Elsevier, vol. 120(4), pages 356-361.
    2. Anna-Maria Fontrier & Erica Visintin & Panos Kanavos, 2022. "Correction to: Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries," PharmacoEconomics - Open, Springer, vol. 6(4), pages 629-629, July.
    3. Aris Angelis & Ansgar Lange & Panos Kanavos, 2018. "Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 123-152, January.
    4. Anna-Maria Fontrier & Erica Visintin & Panos Kanavos, 2022. "Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries," PharmacoEconomics - Open, Springer, vol. 6(3), pages 315-328, May.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Grace Mitchell & Sreeram V. Ramagopalan, 2024. "The Blurred Lines of HTA Agency Decision Making," Medical Decision Making, , vol. 44(1), pages 3-4, January.
    2. Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
    3. Anderson, Michael & Drummond, Michael & Taylor, David & McGuire, Alistair & Carter, Paul & Mossialos, Elias, 2022. "Promoting innovation while controlling cost: The UK's approach to health technology assessment," Health Policy, Elsevier, vol. 126(3), pages 224-233.
    4. Karolina Badora & Aleksandra Caban & Cécile Rémuzat & Claude Dussart & Mondher Toumi, 2017. "Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry," Post-Print hal-01722743, HAL.
    5. Kanavos, Panos & Visintin, Erica & Gentilini, Arianna, 2023. "Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries," Social Science & Medicine, Elsevier, vol. 331(C).
    6. Barbara Więckowska & Monika Raulinajtys-Grzybek & Katarzyna Byszek, 2022. "Using the Dynamic SWOT Analysis to Assess Options for Implementing the HB-HTA Model," IJERPH, MDPI, vol. 19(12), pages 1-17, June.
    7. Buczak-Stec, Elżbieta & Goryński, Paweł & Nitsch-Osuch, Aneta & Kanecki, Krzysztof & Tyszko, Piotr, 2017. "The impact of introducing a new hospital financing system (DRGs) in Poland on hospitalisations for atherosclerosis: An interrupted time series analysis (2004–2012)," Health Policy, Elsevier, vol. 121(11), pages 1186-1193.
    8. Maria Katharina Schweitzer & Manuel Nico Dold & Astrid Genet & Klaus Gossens & Thomas Klein-Hessling & Nils Löffler & Matthias Rabel & Andrej Rasch & Eva-Maria Reuter & Jessica Schmelcher & Natalia Wo, 2024. "Shaping a suitable EU HTA dossier template: why the German template is not fit for purpose," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(5), pages 877-888, July.
    9. Anna-Maria Fontrier & Bregtje Kamphuis & Panos Kanavos, 2024. "How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(6), pages 935-950, August.
    10. Malinowski, Krzysztof Piotr & Kawalec, Paweł & Trąbka, Wojciech, 2016. "Impact of patient outcomes and cost aspects on reimbursement recommendations in Poland in 2012–2014," Health Policy, Elsevier, vol. 120(11), pages 1249-1255.
    11. Riswandy Wasir & Sylvi Irawati & Amr Makady & Maarten Postma & Wim Goettsch & Erik Buskens & Talitha Feenstra, 2019. "Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia," PLOS ONE, Public Library of Science, vol. 14(2), pages 1-19, February.
    12. Mónica D. Oliveira & Inês Mataloto & Panos Kanavos, 2019. "Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 891-918, August.
    13. Angelis, A. & Linch, M. & Montibeller, G. & Molina-Lopez, T. & Zawada, A. & Orzel, K. & Arickx, F. & Espin, J. & Kanavos, P., 2020. "Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework," Social Science & Medicine, Elsevier, vol. 246(C).
    14. Fumio Teramae & Tomohiro Makino & Yeongjoo Lim & Shintaro Sengoku & Kota Kodama, 2020. "Impact of Research and Development Strategy on Sustainable Growth in Multinational Pharmaceutical Companies," Sustainability, MDPI, vol. 12(13), pages 1-15, July.
    15. Jonathan Dando & Maximilian Lebmeier, 2020. "A novel valuation model for medical intervention development based on progressive dynamic changes that integrates Health Technology Assessment outcomes with early-stage innovation and indication-speci," Journal of Innovation and Entrepreneurship, Springer, vol. 9(1), pages 1-28, December.
    16. Riswandy Wasir & Sylvi Irawati & Amr Makady & Maarten Postma & Wim Goettsch & Talitha Feenstra & Erik Buskens, 2019. "The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders," PLOS ONE, Public Library of Science, vol. 14(11), pages 1-14, November.
    17. Csanádi, Marcell & Ozierański, Piotr & Löblová, Olga & King, Lawrence & Kaló, Zoltán & Botz, Lajos, 2019. "Shedding light on the HTA consultancy market: Insights from Poland," Health Policy, Elsevier, vol. 123(12), pages 1237-1243.
    18. Wranik, Wiesława Dominika & Zielińska, Dorota Anna & Gambold, Liesl & Sevgur, Serperi, 2019. "Threats to the value of Health Technology Assessment: Qualitative evidence from Canada and Poland," Health Policy, Elsevier, vol. 123(2), pages 191-202.
    19. Mills, Mackenzie & Kanavos, Panos, 2022. "How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada," Health Policy, Elsevier, vol. 126(11), pages 1130-1143.
    20. Livio Garattini & Anna Padula, 2020. "HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(1), pages 1-5, February.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:25:y:2024:i:8:d:10.1007_s10198-023-01655-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.